BNP Paribas notify of 5.08% shareholding in Galapagos
February 09 2015 - 1:37AM
Galapagos NV (Euronext: GLPG) received a transparency
notification from BNP Paribas.
Pursuant to Belgian transparency legislation1, Galapagos
received a transparency notification on 5 February 2015 from BNP
Paribas Investment Partners SA, BNP Paribas Asset Management SAS,
BNP Paribas Investment Partners Belgium SA, BNP Paribas Investment
Partners UK Ltd. and CamGestion SA. BNP Paribas notified that on 30
January 2015, these entities under their control held 1,538,622
shares, representing 5.08% of the current 30,299,129 outstanding
Galapagos shares. This is the first transparency notice Galapagos
received from BNP Paribas.
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a clinical-stage
biotechnology company specialized in the discovery and development
of small molecule medicines with novel modes of action, with a
pipeline comprising three Phase 2 programs, two Phase 1 trials,
five pre-clinical studies, and 25 discovery small-molecule and
antibody programs in cystic fibrosis, inflammation, and other
indications. In the field of inflammation, AbbVie and
Galapagos signed a collaboration agreement for the development and
commercialization of GLPG0634. GLPG0634 is an
orally-available, selective inhibitor of JAK1 for the treatment of
rheumatoid arthritis and potentially other inflammatory diseases,
currently in Phase 2b studies in RA and in Phase 2 in Crohn's
disease. GLPG1205, a first-in-class inhibitor of GPR84, is
currently being tested in a Phase 2 proof-of-concept trial in
ulcerative colitis patients. GLPG1690 is a compound that
targets pulmonary diseases and is currently in a Phase 1
trial. AbbVie and Galapagos also signed a collaboration
agreement in cystic fibrosis to develop and commercialize molecules
that address mutations in the CFTR gene. Potentiator GLPG1837
is currently in a Phase 1 trial, and corrector GLPG2222 is at the
pre-clinical candidate stage. The Galapagos Group, including
fee-for-service subsidiary Fidelta, has approximately 400
employees, operating from its Mechelen, Belgium headquarters and
facilities in The Netherlands, France, and Croatia. Further
information at: www.glpg.com
CONTACT
Galapagos NV
Elizabeth Goodwin, Head of Corporate
Communications & IR
Tel: +31 6 2291 6240
ir@glpg.com
This release may contain forward-looking statements, including,
without limitation, statements concerning anticipated progress,
objectives and expectations regarding the commercial potential of
our product candidates, intended product development, clinical
activity timing, and other objectives and explanations, all of
which involve certain risks and uncertainties. These statements are
often, but are not always, made through the use of words or phrases
such as "believes," "anticipates," "expects," "intends," "plans,"
"seeks," "estimates," "may," "will," "could," "stands to,"
"continues," "we believe," "we intend," as well as similar
expressions. Such forward-looking statements may involve known and
unknown risks, uncertainties and other factors which might cause
the actual results, financial condition, performance or
achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial
conditions, performance or achievements expressed or implied by
such forward-looking statements. Among the factors that may result
in differences are the inherent uncertainties associated with
competitive developments, clinical trial and product development
activities, regulatory approval requirements and estimating the
commercial potential of our product candidates. Given these
uncertainties, the reader is advised not to place any undue
reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this
document. Galapagos expressly disclaims any obligation to update
any such forward-looking statements in this document to reflect any
change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is
based, unless required by law or regulation.
1 Belgian Act of 2 May 2007 on the disclosure of major
shareholdings in issuers whose shares are admitted to trading on a
regulated market)
HUG#1892604
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024